BioLargo, Inc. · OTC:BLGO
BioLargo — Shareholder Meeting (June 2023)
55 slides from BioLargo's shareholder meeting presentation, Jun 6, 2023
Slide 1: Annual Meeting of Stockholders
BioLargo’ Annual Meeting of Stockholders June 6, 2023 OTCQB: BLGO Westminster, CA
Slide 2: We Make Life Better
We Make Life Better b BioLargo oo (© BioLargo (6) BioLargo Water — L NVIENVIRONMENTAL wo EN=RGY cl “RA — ON Se TECHNOLOGIES Ww Ww Environmental Group cdical subsidia (0 spin-out whe
Slide 3: Who we are
Who we are > Innovators, engineers, and > Passionate about > Driven to make solutions that scientists driven to find or sustainability, environmental are affordable — and thus create new solutions to stewardship, and safeguarding accessible — by people around make life better. human health. the worl
Slide 4: What we do
What we do > Invent, develop, and commercialize > Combine best practices in > Focus on specific, pressing BEST-IN-CLASS technologies that process engineering with problems that don’t have solve major problems in outside-the-box technology good current solutions. environmental remediation, water desi
Slide 5: 5-Year Revenue
5-YEAR REVENUE 0 60 50 gue g = 0 132% annual increasevs. = 2021 so $00 -_ a 2020 2ozt 222 Trends are not necessarily indicative of future performance
Slide 6: 5-Year Debt
5-YEAR DEBT. $70 so $00 2018 2019 2020 2021 2022 Trends are not necessarily indicative of future performance
Slide 7: 5-Year Net Cash Used in Operating Activities
5-YEAR NET CASH USED IN OPERATING ACTIVITIES meRevenue “te Net Cash Used in Operating Activities 00 2018 2019 2020 2021 Trends are not necessarily indicative of future performance
Slide 8: Net Stockholder's Equity (5.25 Years)
$40 $30 $20 so MILLIONS “$10 $20 -$30 2018 NET STOCKHOLDER'S EQUITY (5.25 YEARS) 2021 2022 Increase of >$5.5 million $3.55M 2023 (QIONLY) Trends are not necessarily indicative of future performance (sBiotarco 5
Slide 9: Quarterly Revenue (2021 to Q1 2023)
$40 $3.5 $3.0 $25 $2.0 MILLIONS $15 $10 $0.5 $0.0 QUARTERLY REVENUE (2021 TO Q1 2023) —e Revenue Caveat: + Spike in Q1 Ls ai Q + We expect fluctuations in future quarterly revenue as Pooph establishes new national retail accounts initial Walmart stocking orders of Pooph + Accordingly, we expect a re
Slide 10: Revenue vs Net Loss
REVENUE VS NET LOSS —e-Revenue -e-Net Loss $5.0 $4.0 $3.0 $2.0 $10 MILLIONS $0 $10 $2.0 -$3.0 Trends are not necessarily indicative of future performance Bete {ie
Slide 11: Revenue vs SG&A
$4.0 $3.5 $3.0 $2.5 $2.0 MILLIONS $15 $10 $0.5 $0.0 ai Q2 2021 Q3 REVENUE VS SG&A eH Revenue —s-SGRA a4 a Q2 2022 Q3 a4 qi 2023 Trends are not necessarily indicative of future performance Bictargo ”
Slide 12: Revenue vs Net Cash Generated/Used in Operating Activities
$4.0 $3.0 $2.0 $1.0 MILLIONS $0 $1.0 ~$2.0 REVENUE VS NET CASH GENERATED/USED IN OPERATING ACTIVITIES e-Revenue —e- Net cash used/generated in operating activities Trends are not necessarily indicative of future performance (sBietarge | 2
Slide 13: Additional Financial Information
Additional Financial Information Consolidated Q1 2023 revenues 288% greater than Q1 2022 Revenues “Net loss reduced to $494,000, down from $3,742,000 $1,544,000 in Q1 2022 (68% ston’ “Substantially improved cash position: $3,264,000, revenue Qt compared to $974,000 in Q1 2022 Subsidiaries ONM BioLar
Slide 14: Key Catalysts Driving Value
Key Catalysts Driving Value "= Callahan MLD i
Slide 15: ONM Environmental Products and Services
__ Wf" \O__ CINMIENVIRONMENTAL PRODUCTS AND SERVICES.
Slide 16: Unsurpassed Odor Control
Unsurpassed Odor Control Without Fragrances, Enzymes or Chlorine Compounds (sBioLarge
Slide 17: Our odor control systems
Slide 18: Current industries served
Current industries served 2. Automotive (paint emissions) 1 Municipal Solid 3. Wastewater Treatment Waste 4. Rendering 5. Food Processing 6. Asphalt Manufacturing > Customers include largest waste handlers in the country, County of Orange, Santa Barbara County, LA County, Miami-Dade County, City of
Slide 19: Odor emissions testing and other value-add services
> Odor emissions testing and Other value-add services Air quality testing qualification Site surveys Landfill consulting (operations, staffing, expansion) Environmental engineering services GBiotargo | 12
Slide 20: CupriDyne White/Private Label Products
aN a CupriDyne’ Cociean White/Private Label Products > ONM maintains Industries Served Potential new clients manufacturing Pet in the works! “Household Automotive “Artificial Turf Biotago 20
Slide 21: POOPH Pet
POOPH Pet Q Veteran CPG marketeers Q Multiple SKUs Q New CupriDyne-based products coming Q Approx. $2.8M in revenue for 2022 Q Approx. $3.1M in revenue in first quarter 2023 Q ONNM receives a manufacturer's margin and a royalty on sales Q We receive 20% if brand is sold
Slide 22: Special Guest — Jane Pak
Special Guest — Jane Pak + Jane Pak, Co-Founder and CEO of Ikigai Marketing Works, LLC, * CEO and Board Chair at Pooph, Inc. (Biobargo | a2
Slide 23: Ikigai Shareholder Meeting
BIOLARGO SHAREHOLDER IKIGAT MEETING JUNE 6, 2023 CONFIDENTIAL
Slide 24: How can you break into an impossible category?
HOW CAN YOU BREAK INTO RISING NSS [@]B) AN IMPOSSIBLE CATEGORY? [§R@)EDRUSH TO} 79% OF PET OWNERS REDEFINE ODOR VALIDATED THEY HAD AN "ELIMINATION" ON-GOING ODOR PROBLEM BIOLARGO'S TECHNOLOGY [RSESSuINeX@)Siinl=esi=\ iad & PEDIGREE CAN'T COMPETE WITH THE EFFICACY AND HISTORY CONFIDENTIAL
Slide 25: Launch to Date Highlights
LAUNCH TO DATE HIGHLIGHTS NOVEMBER 6, 2021 LAUNCH 18 MONTHS Q4 V. QI RATE OF CHANGE 13% DTC INCREASE IN REVENUE 5% DECREASE WEB SALES $26.8+ M DTC REVENUE 24% INCREASE IN AMAZON SALES 814+ K DTC ORDERS 1M+ BOTTLES SHIPPED 7,300+ 5-STAR REVIEWS 14,840+ SUBSCRIBERS 21% REPEAT PURCHASE 688% GROWTH Q0Q
Slide 26: Ebbs & Flows of the Ikigai Method
EBBS & FLOWS OF THE IKIGAI METHOD Timing details around purchasing - (Lumpy Phase) ¢ DTC decreases as retail increases ¢ Sell Thru Rate drives inventory purchasing Factors that impact purchasing timing ¢ When Retailers place POs ¢ How quickly retailers stock stores * Retail health & Seasonal-related
Slide 27: Early Retail Highlights
EARLY RETAIL HIGHLIGHTS 22-0ct CONFIDENTIAL Units Shipped = Revenue $100,000 $200,000 $300,000 $ 400,000 $50¢ 10,000 691% GROWTH RETAIL GROWTH QOQ 181% GROWTH AVERAGE MOM WALMART GROWTH 1,264% GROWTH MOM CHEWY GROWTH. 277% GROWTH CHEWY V. WALMART GROWTH
Slide 28: 2023-2024 Retailers
ie Walmart >< rvs see 15° chewy.2 sme Q ymax 15 Bae 2023-2024 10° Oe i RETAILERS 10% ... 1, (outa ceNenae)
Slide 29: Thank You
THANK YOU FOR AN INCREDIBLE Y oeenm PARTNERSHIP) => z
Slide 30: BioLargo Engineering (BLEST)
(sBietarge | 30
Slide 31: BLEST Business Goals
BLEST Business Goals > Commercial scale-up of AEC PFAS tech > Develop methodology for destruction of PFAS waste from AEC membranes > Expand AEC into new markets > Execute waste-to-energy opportunities > Service existing clients Bictargo
Slide 32: BLEST Year in Review
BLEST Year in Review Record year AEC PFAS — prepared for full-scale roll-out First PFAS customer Multiple PFAS testing program engagements Battery manufacturing project - designed and commenced USNC prototype project successful and expanded Waste-to-Energy Phase | complete New York chemical plant Ph
Slide 33: Commercialization of the AEC Technology
Commercialization of the AEC Technology > Commercial opportunities (municipal, industrial, food service retail) increasing at a high rate. > Sales and marketing efforts * Tonya Chandler to expand discussion later in presentation > Ruggedization (Service Life Extension) > Expanding markets (smaller f
Slide 34: BioLargo Sodium-Sulfur Battery
BioLargo Sodium-Sulfur Battery > Better option for long duration energy storage (LDES), an important emerging market Compared to other battery technologies: Pictured: single stondard DD cel Each 25kWhunit comprised of -1000 ces. (sBioLarge
Slide 35: Compared to other batteries
Compared to other batteries Natron Energy Ambri BioLargo Battery (liquid metal) (Sodium Sulfur) Energy density (Wh/kg) 150-190 75-165 Low 552 Life cycle (down to 80% - discharge) 500-1,000 100,000. No loss in discharge No loss in discharge Open circuitcell voltage (V) 3.7 2] -25 42 Operating tempera
Slide 36: Considering the Battery Opportunity
Considering the Battery Opportunity + Electrification of nation will require one terawatt of new generating capacity * Renewable energy necessitates storage expansion + Every solar farm and wind energy site will require a Battery Energy Storage System (BESS) + The eventual need will be up to 10,000
Slide 37: Commercializing the Battery Technology
Commercializing the Battery Technology Laboratory and prototype manufacturing facility under construction now Construct various sized prototypes Validate historical performance data Construct commercial-size arrays for testing and demonstration Design grid-scale storage system (1 MW-hr) Expand staff
Slide 38: BioLargo Water
() BioLargo Water (itara0 [an
Slide 39: Uniquely valuable against micropollutants
Uniquely valuable against micropollutants for expanding market Low cost — Energy Efficient — Extreme Performance Broad-spectrum disinfection with no significant by-products Applications in numerous water treatment markets
Slide 40: Continual Design Improvements
Continual Design Improvements ©) & Improved Improved Real time efficiency performance monitoring Biotargo 40
Slide 41: A solution for emerging contaminants
A solution for emerging contaminants Exceptional at removal of pharmaceuticals Current technologies inefficiently remove pharmaceuticals AOS proven to improve municipal plant's performance AOS is a viable solution to the emerging European micropollutants market (EU Urban Wastewater Treatment Directi
Slide 42: AEC Pilot Project in Montreal
AEC Pilot Project in Montreal 60 mins m1 120 mins m 180 mins = 240 mins m 300 mins m 360 mins + Proof of concept study + 71-94% removal of examined PFAS compounds in municipal wastewater Removal efficiency (%) PFOA PFBA PBS -~—~PFOS. PFAS compound
Slide 43: What's next for BioLargo Water
What's next for BioLargo Water Partnerships Commercial case Poultry drinking studies for water reuse > Decontamination > Claims targeted at EU water for new > Wastewater as a service clients BLEST client GBiolago
Slide 44: Ongoing Commercialization Efforts
We Make Life Better r(s BioLargo Ongoing Commercialization Efforts go Portfolio of Water Treatment Equi GBiobargo as
Slide 45: Considering the Emerging PFAS Market - USA
Considering the Emerging PFAS Market - USA > EPA recently proposed very stringent treatment standards (4 ppt) > Creates potential for significant growth in target market > Candidates for PFAS treatment customers: + Potable Water — 148,000 public water systems in the US! + Wastewater Treatment Outfal
Slide 46: Race to PFAS
Race to PFAS Market Has Many Obstacles 9s before achieving mass market 1, Overcome resistance from market ‘lutions 2. Early adopters first 3. Generate reference customer data 5. Scaled mai 9 6. Use success of reference customer(s) to achieve wider market adoption
Slide 47: 2022 Achievements
2022 Achievements > Built a network of channel partners and sales reps covering North America > Signed our first commercial customer > Completed PFAS testing program studies > Completed a pilot scale run of the Garratt-Callahan technology > Showcased at multiple tradeshows to introduce our technolog
Slide 48: 2023 Goals
2023 Goals > Install large trailerized AEC for PFAS removal > Validate AEC capabilities for wastewater and leachate > Contract commercial installations for Garratt-Callahan system > Expand commercial activities featuring equipment catalogue through existing selling channels > Continue building reput
Slide 49: 2023 Current status
2023 Current status Phase II scoped and bid for current industrial site client. Verbal commitment from client, awaiting contract. First full-scale AEC system going to bid Listed on EPA website Scoped and bid on projects valued at approximately $15M New potential AOS commercialization partners Garrat
Slide 50: 2023 Industry Engagements as PFAS Expert
2023 Industry Engagements as PFAS Expert > Averaging 2-4 invited presentations to industry leaders per month: engineering firms, associations, and key industry events > Extensive tradeshow participation scheduled > Widely sought after and engaged as expert speaker on PFAS, including legal and engine
Slide 51: Clyra Medical Technologies Inc
CLYRA Medical Technologies Inc (Bitees |
Slide 52: Clyra Status Summary
Clyra Status Summary * Choke point technologies * Bioclynse launch + Expanding network of sales C LY R Nn representatives + In negotiation with strategic Medical Technologies Inc partners + Target health care systems and hospitals + Additions to Clyra board
Slide 53: Highest Value Use Case for Product
Highest Value Use Case for Product @ cra Average orthopedic surgeon - 20 surgeries per month 2 liters of Bioclynse will typically be used during a procedure at $150/liter representing $6,000/month revenue per surgeon 200 surgeons: $14,400,000 in annual revenue 31,000 practicing orthopedic surgeons i
Slide 54: Comparison to other products
Comparison to other products Product Bioclynse (Clyra WIS) Prontosan (B Braun) Bactisure (Zimmer) Irrisept (Irrimax Corp) Penvelineis (ena copper iodine complexplatform — PHMB (0.1%) BAK & Acetic acid CHG (0.05%) VEsietaton Biofim disruption Hes pean cow Biofilm disruption Biofilm disruption Antimic
Slide 55: The BioLargo Family of Companies
The BioLargo 6 Family of Companies BioLargo Make Ue Bette BioLargo, Inc. is a sustainable science, technology & full-service enviromental engineering company that makeslifebetter by delivering world-class Genoa, products and services across a broad range of industries, wth a drive to deliver lean wa